Michelle A Pressly,Robert Schuck,Padmaja Mummaneni et al.
Michelle A Pressly et al.
The development of polygenic risk scores (PRSs), which make use of genetic testing to assess an individual's risk of developing certain diseases or conditions based on collective genetic variant information, can be applied in drug developme...
Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeutics [0.03%]
药物基因组学与罕见病：优化新药开发及个体化治疗
Youssef M Roman
Youssef M Roman
Pharmacogenomics (PGx) is an evolving field that integrates genetic information into clinical decision-making to optimize drug therapy and minimize adverse drug reactions (ADRs). Its application in rare disease (RD) drug development is prom...
Impact of CYP2C19 polymorphism testing on the risk of stent thrombosis in patients with carotid artery stenting [0.03%]
细胞色素2C19基因多态性检测对颈动脉支架置入术后支架血栓形成风险的影响
Huai Wu Yuan,Xia Huang,Min Ying Pan et al.
Huai Wu Yuan et al.
Objective: We aimed to identify the impact of CYP2C19 polymorphism testing on clinical outcomes in patients who have undergone carotid artery stenting (CAS). ...
Pharmacogenomic markers associated with drug-induced QT prolongation: a systematic review [0.03%]
与药物引起QT延长有关的药理基因组标记物：系统性回顾
Marlene Schouby Bentestuen,Christian Noe Weis,Caroline Bækmann Jeppesen et al.
Marlene Schouby Bentestuen et al.
Aim: To systematically assess clinical studies involving patients undergoing drug therapy, comparing different genotypes to assess the relationship with changes in QT intervals, with no limitations on study design, settin...
Impact of a pharmacogenomics (PGx) clinic on patient satisfaction and PGx literacy [0.03%]
药效基因组学(PGx)诊所对患者满意度和PGx素养的影响
Amanda Massmann,Jordan Baye,Max Weaver et al.
Amanda Massmann et al.
Introduction: Genetic variants can impact medication response. The study of genetic variants on medications is called pharmacogenomics (PGx). Understanding PGx results can be difficult as results are reported differently ...
Lindy Maska,Roseann S Donnelly,Benjamin J Kerman et al.
Lindy Maska et al.
Aim: To assess patient perspectives following evaluation in a multidisciplinary pharmacogenomics clinic run by a clinical pharmacist, genetic counselor, and physician. ...
Reinterpretation of pharmacogenomic phenotypes after combinatorial psychiatric testing [0.03%]
精神科联合检测后对药物基因组表型的新解释
Michele Cung,John Loftus,Mark A Marzinke et al.
Michele Cung et al.
Aim: Providers can use combinatorial pharmacogenomic panels to aid psychiatric medication prescribing. Results are typically documented in static documents which list the genotype and predicted phenotype (interpretation)....
Treatment of extended RAS/ BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations [0.03%]
抗EGFR抗体组合治疗扩增的RAS/BRAF野生型转移性结直肠癌
Ioannis A Voutsadakis
Ioannis A Voutsadakis
Receptor tyrosine kinase pathways are frequently deregulated in cancer. Inhibiting these pathways with small molecule inhibitors or monoclonal antibodies has become a crucial addition to the therapeutic armamentarium in oncology. Since the ...
Posttransplantation diabetes mellitus (PTDM): pharmacological aspects and genetic predispositions [0.03%]
移植后糖尿病（PTDM）：药物作用和遗传易感性
Dorian Chastagner,Hélène Arnion,Clément Danthu et al.
Dorian Chastagner et al.
Posttransplantation diabetes mellitus (PTDM) is a form of diabetes developed after solid organ or stem cell transplantation. This condition shares physiopathological traits with type 2 diabetes, including insulin resistance and β-cells dys...
Pasquale Paribello,Ulker Isayeva,Claudia Pisanu et al.
Pasquale Paribello et al.
Aims: The present review explores the existing evidence on pharmacogenomic tests for prediction of lithium response in the treatment of bipolar disorder. We focused our research article on reports describing findings from...